Lincoln PharmaceuticalsNSE:LINCOLN -0.65%81 Interest Coverage is 77.16 as of Mar. 2026, which is 60% above its 10-year median of 48.16. GuruFocus rates NSE:LINCOLN with a GF Score™ of 81/100 and a GF Value™ of ₹704.04 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 686 Drug Manufacturers companies, Lincoln Pharmaceuticals ranks better than 76.38% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lincoln Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was ₹212 Mil. Lincoln Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was ₹-3 Mil.
Lincoln Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 77.16.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Lincoln Pharmaceuticals Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Lincoln Pharmaceuticals's Interest Coverage or its related term are showing as below:
NSE:LINCOLN'
s Interest Coverage Range Over the Past 10 Years
Min: 7.48 Med: 48.16 Max: 96.1
Current: 82.12
NSE:LINCOLN's Interest Coverage is ranked better than 76.38% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs NSE:LINCOLN: 82.12
Lincoln Pharmaceuticals (NSE:LINCOLN) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lincoln Pharmaceuticals Interest Coverage Related Terms
Lincoln Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Lincoln Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:LINCOLN vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's Interest Coverage falls into.
Lincoln Pharmaceuticals Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Interest Coverage of 77.16 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lincoln Pharmaceuticals and its competitors. This is 60% above median its historical median of 48.16. Over the past decade, Lincoln Pharmaceuticals' Interest Coverage has ranged from 7.48 to 96.10. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #162 out of 686 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Lincoln Pharmaceuticals' Interest Coverage too high?
Lincoln Pharmaceuticals' current Interest Coverage of 77.16 is 60% above median its 10-year median of 48.16. Over the past 10 years, this metric has ranged from a low of 7.48 to a high of 96.10. The Drug Manufacturers industry median Interest Coverage is 12.73. Lincoln Pharmaceuticals' value of 77.16 is 506.4% above this industry median. Based on the distribution chart, Lincoln Pharmaceuticals ranks #162 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lincoln Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #162 out of 686 companies for Interest Coverage. This places Lincoln Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.73. Lincoln Pharmaceuticals' value of 77.16 is 506.4% above this benchmark. Historically, Lincoln Pharmaceuticals' own Interest Coverage has ranged from 7.48 to 96.10 over the past decade. While the company's 10-year median is 48.16 vs. the industry median of 12.73, Lincoln Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lincoln Pharmaceuticals's current Interest Coverage of 77.16 is 506.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current Interest Coverage is 77.16, which is 60% above median its own 10-year median of 48.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹704.04, compared to a current price of ₹620.20 — trading 11.9% below its estimated fair value. The current Interest Coverage is 77.16, which is 60% above median its 10-year median of 48.16 and 506.4% above the Drug Manufacturers industry median of 12.73. Lincoln Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Interest Coverage is 77.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹620.20 is trading 11.9% below its estimated GF Value™ of ₹704.04.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
Interest Coverage: 77.16 (60% above median its 10-year median of 48.16)
GF Value™: ₹704.04 vs. price of ₹620.20 (11.9% below fair value)
Industry Position: 506.4% above the Drug Manufacturers median (#162 of 686)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
81GF Score
Get the complete analysis for NSE:LINCOLN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
